Caydan Portfolio Company MitoSense Secures U.S. Patent for Mitochondria-Based Therapy for Neurodegenerative Diseases

Plymouth, MA - Caydan Capital Partners announced today that its portfolio company, MitoSense, Inc., a pioneering research and development company focused on treatments for neurodegenerative diseases, has been issued U.S. Patent No. 12,150,958, titled "Compositions and Methods for Treatment of Amyotrophic Lateral Sclerosis (ALS) and Other Neurodegenerative Diseases, and Associated Methods for Preparing Said Compositions." This patent marks a significant milestone in the company's mission to develop groundbreaking therapies.

‍

The newly secured patent protects MitoSense's proprietary techniques for Mitochondria Organelle Transplantation (MOT™), a method aimed at replenishing mitochondria in human cells to treat ALS and potentially a range of other neurodegenerative diseases, including Alzheimer's, Parkinson's, Huntington's, and Multiple Sclerosis. This innovative approach, developed through extensive research, offers a promising avenue for addressing diseases that currently lack effective cures.

‍

MitoSense's MOT™ technology is founded on a robust base of scientific innovation and dedicated research, initiated by the late Dr. Robert Elliott, MD, PhD. The company's leadership team, composed of experts from the business, government, research, and medical sectors, is committed to advancing Dr. Elliott's legacy and providing hope for patients and families affected by neurodegenerative diseases.

‍

Van Hipp, Chairman of MitoSense, Inc., commented on the milestone: "The issuance of this patent is a tremendous achievement for MitoSense and underscores our commitment to innovation in the fight against neurodegenerative diseases. Our MOT™ technology has the potential to revolutionize how we treat conditions like ALS, Alzheimer's, and Parkinson's. This is a significant step forward in our mission to bring transformative treatments to patients who desperately need them."

‍

About MitoSense Inc.

MitoSense Inc. is at the forefront of mitochondrial research, committed to developing pioneering solutions that harness the potential of mitochondria to transform treatments for various medical conditions. For further information about MitoSense and its research efforts, visit https://www.mitosense.com or contact the company at [email protected].

‍

About Caydan Capital Partners

Caydan Capital Partners is a Boston, Massachusetts-based private equity firm focused on control investments in growth-oriented companies in the North American lower middle market. With offices in Boston, Dallas, and Puerto Rico, Caydan provides investors with access to a historically less accessible segment of the market through a diversified investment platform spanning private equity, public equity, and venture capital. For more information, please visit https://www.caydancapital.com/.

‍